COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series

Discussion Based on a review of available information, the risk of more severe COVID-19 in patients receiving fingolimod or siponimod seems to be similar to that reported in the general population and the MS population with COVID-19. However, limitations of spontaneous reporting, especially missing data, should be considered in the interpretation of these observations.

http://nn.neurology.org/cgi/content/short/9/1/e1092?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - November 30, 2021 Category: Neurology Authors: Sullivan, R., Kilaru, A., Hemmer, B., Campbell Cree, B. A., Greenberg, B. M., Kundu, U., Hach, T., DeLasHeras, V., Ward, B. J., Berger, J. Tags: COVID-19, Multiple sclerosis Article Source Type: research